Integrin β3 Expression on New Blood Vessels (CD61) of FaDu Xenografts in Control Mice or Mice Treated with Bevacizumab, Sorafenib, or Local Irradiation
| Time after treatment (d) | Control | Bevacizumab | Sorafenib | Irradiation |
| 3 | + | ++ | ||
| 10 | +++ | +++ | ||
| 21 | +++ | ++ | ||
| 2 | + | + | ||
| 5 | ++ | ++ | ||
| 9 | +++ | +++ | ||
| 19 | ++ | +++ | ||
| 0.17 | ++ | ++ | ||
| 1 | ++ | ++ | ||
| 3 | ++ | ++ | ||
| 10 | ++ | + |
↵+ = ≤5%; ++ = 6%–10%; +++ = 11%–20%.